Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics

Alzheimer’s disease (AD) is a common chronic and destructive disease. The early diagnosis of AD is difficult, thus the need for clinically applicable biomarkers development is growing rapidly. There are many methods to biomarker discovery and identification. In this review, we aim to summarize Mass...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yahui, Qing, Hong, Deng, Yulin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057708/
https://www.ncbi.nlm.nih.gov/pubmed/24806343
http://dx.doi.org/10.3390/ijms15057865
_version_ 1782321015258349568
author Liu, Yahui
Qing, Hong
Deng, Yulin
author_facet Liu, Yahui
Qing, Hong
Deng, Yulin
author_sort Liu, Yahui
collection PubMed
description Alzheimer’s disease (AD) is a common chronic and destructive disease. The early diagnosis of AD is difficult, thus the need for clinically applicable biomarkers development is growing rapidly. There are many methods to biomarker discovery and identification. In this review, we aim to summarize Mass spectrometry (MS)-based proteomics studies on AD and discuss thoroughly the methods to identify candidate biomarkers in cerebrospinal fluid (CSF) and blood. This review will also discuss the potential research areas on biomarkers.
format Online
Article
Text
id pubmed-4057708
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-40577082014-06-16 Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics Liu, Yahui Qing, Hong Deng, Yulin Int J Mol Sci Review Alzheimer’s disease (AD) is a common chronic and destructive disease. The early diagnosis of AD is difficult, thus the need for clinically applicable biomarkers development is growing rapidly. There are many methods to biomarker discovery and identification. In this review, we aim to summarize Mass spectrometry (MS)-based proteomics studies on AD and discuss thoroughly the methods to identify candidate biomarkers in cerebrospinal fluid (CSF) and blood. This review will also discuss the potential research areas on biomarkers. Molecular Diversity Preservation International (MDPI) 2014-05-06 /pmc/articles/PMC4057708/ /pubmed/24806343 http://dx.doi.org/10.3390/ijms15057865 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Liu, Yahui
Qing, Hong
Deng, Yulin
Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics
title Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics
title_full Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics
title_fullStr Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics
title_full_unstemmed Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics
title_short Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics
title_sort biomarkers in alzheimer’s disease analysis by mass spectrometry-based proteomics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057708/
https://www.ncbi.nlm.nih.gov/pubmed/24806343
http://dx.doi.org/10.3390/ijms15057865
work_keys_str_mv AT liuyahui biomarkersinalzheimersdiseaseanalysisbymassspectrometrybasedproteomics
AT qinghong biomarkersinalzheimersdiseaseanalysisbymassspectrometrybasedproteomics
AT dengyulin biomarkersinalzheimersdiseaseanalysisbymassspectrometrybasedproteomics

Ejemplares similares